Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease.

abstract：BACKGROUND:Disease outcome in Crohn's disease might have changed during the last four decades. Disease outcome measurement in Crohn's disease has methodological difficulties because of patient selection and lack of proper definition of diagnostic and outcome measurement criteria. AIM:To assess possible changes in dise...

journal_title：Alimentary pharmacology & therapeutics

authors： Wolters FL,Russel MG,Stockbrügger RW

更新日期：2004-09-01 00:00:00

abstract：BACKGROUND:There has been growing interest in the use of faecal microbiota transplantation (FMT) for the treatment of gastrointestinal and nongastrointestinal diseases. AIM:To review systematically the reported efficacy and safety of FMT in the management of gastrointestinal and nongastrointestinal disorders in adults...

journal_title：Alimentary pharmacology & therapeutics

authors： Sha S,Liang J,Chen M,Xu B,Liang C,Wei N,Wu K

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:The use of healthcare resources for the management of constipation is not well-known. AIM:To analyse healthcare seeking for constipation, defined by three different criteria, and its related factors and to assess the frequency of use of laxatives, suppositories and enemas for the treatment of constipation. ...

journal_title：Alimentary pharmacology & therapeutics

authors： Gálvez C,Garrigues V,Ortiz V,Ponce M,Nos P,Ponce J

更新日期：2006-07-15 00:00:00

abstract：BACKGROUND:Anti-ulcer agents exert various functional effects on gastric epithelial cells. AIM:The effects of a novel gastro-cytoprotective agent (rebamipide) on epithelial restoration following bile acid damage were assessed using primary cultured rabbit gastric epithelial cells. METHODS:Rebamipide was added to comp...

journal_title：Alimentary pharmacology & therapeutics

authors： Watanabe S,Wang XE,Hirose M,Yoshizawa T,Iwazaki R,Oide H,Kitamura T,Miwa H,Miyazaki A,Sato N

更新日期：1996-12-01 00:00:00

abstract：BACKGROUND:Anti-TNFα agents have revolutionised management of chronic inflammatory diseases. Paradoxically, these agents might provoke development of de novo autoimmune diseases. AIM:To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with ...

journal_title：Alimentary pharmacology & therapeutics

authors： Korzenik J,Larsen MD,Nielsen J,Kjeldsen J,Nørgård BM

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:Treatment options for non-alcoholic steatohepatitis (NASH) are limited. Weight loss remains the most recommended therapy. Orlistat is an effective adjunct to dietary weight loss therapy. AIM:To evaluate the efficacy of orlistat, given for 6 months to patients with obesity and biopsy confirmed NASH. METHODS...

journal_title：Alimentary pharmacology & therapeutics

authors： Harrison SA,Fincke C,Helinski D,Torgerson S,Hayashi P

更新日期：2004-09-15 00:00:00

abstract：BACKGROUND:The Th2 allergic pathway in eosinophilic oesophagitis (EoE) responds to food antigen exposure. AIM:To compare the presence and temporal pattern of food antigen penetration in oesophageal mucosa in active and inactive EoE and controls METHODS: Thirty-two patients with EoE (20 active) and 10 controls were ask...

journal_title：Alimentary pharmacology & therapeutics

authors： Ravi A,Marietta EV,Alexander JA,Peterson K,Lavey C,Geno DM,Murray JA,Katzka DA

更新日期：2021-02-01 00:00:00

abstract：BACKGROUND:Benzodiazepines are used as sedatives for some intestinal procedures and as hypnotics, and this is the reason for studying their effects on duodenojejunal motility. METHODS:Antroduodenojejunal manometry was performed in 13 healthy volunteers on two different occasions, when placebo or midazolam were given i...

journal_title：Alimentary pharmacology & therapeutics

authors： Castedal M,Björnsson E,Abrahamsson H

更新日期：2000-05-01 00:00:00

abstract：BACKGROUND:Butyrate, propionate and acetate are short chain fatty acids (SCFA), important for maintaining a healthy colon and are considered as protective in colorectal carcinogenesis. However, they may also regulate immune responses and the composition of the intestinal microbiota. Consequently, their importance in a ...

journal_title：Alimentary pharmacology & therapeutics

authors： Gill PA,van Zelm MC,Muir JG,Gibson PR

更新日期：2018-07-01 00:00:00

abstract：BACKGROUND:Limited therapeutic options exist for severe gastroparesis, where severe nausea and vomiting can lead to weight loss, dehydration and malnutrition due to inadequate caloric and fluid intake. TZP-101 (ulimorelin) is a ghrelin receptor agonist that accelerates gastric emptying and improves upper gastrointestin...

journal_title：Alimentary pharmacology & therapeutics

authors： Wo JM,Ejskjaer N,Hellström PM,Malik RA,Pezzullo JC,Shaughnessy L,Charlton P,Kosutic G,McCallum RW

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:Acute liver failure is a rare and devastating clinical condition resulting from sudden loss of hepatic parenchyma and metabolic function. The Scottish Liver Transplant Unit (SLTU) offers specialist management and emergency liver transplantation to patients with acute liver failure from across Scotland. AIM:...

journal_title：Alimentary pharmacology & therapeutics

authors： Donnelly MC,Davidson JS,Martin K,Baird A,Hayes PC,Simpson KJ

更新日期：2017-03-01 00:00:00

abstract：:Irritable bowel syndrome is a disease that can be diagnosed positively on the basis of an established series of criteria and limited exclusion of organic disease. It is the most common disease diagnosed by gastroenterologists and affects about 20% of all people at any one time. Symptoms fluctuate, and the overall prev...

journal_title：Alimentary pharmacology & therapeutics

authors： Camilleri M,Choi MG

更新日期：1997-02-01 00:00:00

abstract：:The mode of transmission of Helicobacter pylori is largely unknown and is a matter of circumstantial evidence and speculation rather than fact. However, the principle evidence is of two sorts: the epidemiological data, providing evidence of possible risk factors associated with transmission, and the identification of ...

journal_title：Alimentary pharmacology & therapeutics

authors： Vaira D,Holton J,Ricci C,Menegatti M,Gatta L,Berardi S,Tampieri A,Miglioli M

更新日期：2001-06-01 00:00:00

abstract：BACKGROUND:A lack of reliable treatments for abdominal pain-related functional gastrointestinal disorders prompts interest in new therapies. AIM:To evaluate systematically the effect of Lactobacillus rhamnosus GG (LGG) for treating abdominal pain-related functional gastrointestinal disorders in children. METHODS:MEDL...

journal_title：Alimentary pharmacology & therapeutics

authors： Horvath A,Dziechciarz P,Szajewska H

更新日期：2011-06-01 00:00:00

abstract：:The effects of treatment with the Chinese herbal medicine Liu-Jun-Zi-Tang (TJ-43) on gastric emptying and gastrointestinal symptoms were investigated in 42 patients with chronic idiopathic dyspepsia. By random allocation, 22 patients received oral treatment with 2.5 g TJ-43 three times daily, and 20 patients received ...

journal_title：Alimentary pharmacology & therapeutics

authors： Tatsuta M,Iishi H

更新日期：1993-08-01 00:00:00

abstract：BACKGROUND:Local delivery of therapeutic agents to the stomach may be a useful strategy in the treatment of Helicobacter pylori infection. We aimed to see whether the intragastric distribution and gastric retention of a therapeutic agent could be improved, either by giving omeprazole or by dosing after a meal. METHODS...

journal_title：Alimentary pharmacology & therapeutics

authors： Atherton JC,Washington N,Bracewell MA,Sutton LJ,Greaves JL,Perkins AC,Hawkey CJ,Spiller RC

更新日期：1994-10-01 00:00:00

abstract：BACKGROUND:Antibiotic prophylaxis seems to decrease the incidence of bacterial infections in patients with cirrhosis and upper gastrointestinal bleeding and is considered standard of care. However, there is no updated information regarding the effects of this intervention. AIM:To assess the benefits and harms of antib...

journal_title：Alimentary pharmacology & therapeutics

authors： Chavez-Tapia NC,Barrientos-Gutierrez T,Tellez-Avila F,Soares-Weiser K,Mendez-Sanchez N,Gluud C,Uribe M

更新日期：2011-09-01 00:00:00

abstract：BACKGROUND:The duration of Helicobacter pylori eradication regimens has decreased to 1 week with cure rates of over 90%. This can be attributed to the use of triple drug regimens including potent inhibitors of gastric acid secretion and clarithromycin. There is no theoretical reason why shorter regimens should not be p...

journal_title：Alimentary pharmacology & therapeutics

authors： Grimley CE,Penny A,O'sullivan M,Shebani M,Lismore JR,Cross R,Illing RC,Loft DE,Nwokolo CU

更新日期：1999-07-01 00:00:00

abstract：BACKGROUND:There are patients with chronic hepatitis C who are not eligible for the current interferon-based therapies or refuse to be treated due to secondary effects. AIM:To provide information on alternative treatments for the management of these patients. METHODS:A PubMed search was performed to identify relevant...

journal_title：Alimentary pharmacology & therapeutics

authors： Carreño V

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Patients with thalassaemia major depend on blood transfusions. In Italy, up to 80% of thalassaemia patients bear HCV antibodies due to HCV contaminated transfusions before 1990. Thalassaemia patients with HCV infection have high risk of developing HCC. Treatment based on Pegylated-IFN (Peg-IFN) and Ribavirin...

journal_title：Alimentary pharmacology & therapeutics

authors： Mangia A,Sarli R,Gamberini R,Piga A,Cenderello G,Piazzolla V,Santoro R,Caruso V,Quarta A,Ganga R,Copetti M,Forni G

更新日期：2017-08-01 00:00:00

abstract：BACKGROUND:Attainment of intragastric pH < 6.0 may require high-dose continuously infused proton pump therapy. AIM:To assess the pharmacokinetic and pharmacodynamic dose-responses of continuous infusion regimens of lansoprazole. METHODS:Healthy adult subjects were assigned to lansoprazole 60-mg intravenous bolus, fol...

journal_title：Alimentary pharmacology & therapeutics

authors： Howden CW,Metz DC,Hunt B,Vakily M,Kukulka M,Amer F,Samra N

更新日期：2006-04-01 00:00:00

abstract：BACKGROUND:Treatment with a continuous i.v. proton pump inhibitor is presumed to promote clot formation and stability by sustaining intragastric pH > or = 6. AIM:We postulated that very frequent oral dosing of proton pump inhibitors should simulate i.v. infusion and achieve similar pH control. METHODS:Twenty healthy ...

journal_title：Alimentary pharmacology & therapeutics

authors： Pais SA,Nathwani RA,Dhar V,Nowain A,Laine L

更新日期：2006-06-01 00:00:00

abstract：BACKGROUND:Response to proton pump inhibitor (PPI) treatment in dyspepsia is unpredictable. AIM:To identify symptoms associated with response to esomeprazole in order to target patients for empirical treatment. METHODS:Eight hundred and five uninvestigated, primary care patients with upper GI symptoms that were consi...

journal_title：Alimentary pharmacology & therapeutics

authors： Meineche-Schmidt V,Christensen E,Bytzer P

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Direct-acting anti-virals (DAA) are safe, effective treatment of hepatitis C virus (HCV). Suboptimal linkage to specialists and access to DAAs are the leading barriers to treatment; however, data are limited. AIM:To determine predictors of follow-up, receipt of DAAs, and reasons for the lack thereof. METHO...

journal_title：Alimentary pharmacology & therapeutics

authors： Lin M,Kramer J,White D,Cao Y,Tavakoli-Tabasi S,Madu S,Smith D,Asch SM,El-Serag HB,Kanwal F

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:Antibiotic resistance and duration of therapy influence the success of proton-pump inhibitor-containing Helicobacter pylori eradication therapy. Clarithromycin resistance is associated with treatment failure. AIM:To examine the success of a 7-day rabeprazole-clarithromycin-amoxicillin therapy in the study p...

journal_title：Alimentary pharmacology & therapeutics

authors： Cardenas VM,Graham DY,El-Zimaity HM,Opekun AR,Campos A,Chavez A,Guerrero L

更新日期：2006-01-15 00:00:00

abstract：BACKGROUND:A large proportion (25-46%) of adults with inflammatory bowel disease in remission has symptoms of irritable bowel syndrome (IBS), which are thought to reflect ongoing inflammation. Data on paediatric inflammatory bowel disease patients are lacking. AIM:To investigate (i) the prevalence of IBS-type symptoms...

journal_title：Alimentary pharmacology & therapeutics

authors： Diederen K,Hoekman DR,Hummel TZ,de Meij TG,Koot BG,Tabbers MM,Vlieger AM,Kindermann A,Benninga MA

更新日期：2016-07-01 00:00:00

abstract：BACKGROUND:Data on liver transplantation (LT) in acute on chronic liver failure (ACLF) are scanty. AIM:To perform meta-analysis on outcomes after LT for ACLF compared with ACLF patients not receiving LT or with LT recipients for indications other than ACLF. METHODS:We pooled data from 12 studies on LT outcomes among ...

journal_title：Alimentary pharmacology & therapeutics

authors： Abdallah MA,Waleed M,Bell MG,Nelson M,Wong R,Sundaram V,Singal AK

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:Proton pump inhibitor (PPI) use is associated with an increased risk of Clostridium difficile infection (CDI), though the mechanism is unclear. PPI induced alterations to the gut microbiome may facilitate the emergence of CDI, though the effects of PPIs on gut microbiota are not well characterised. [Correcti...

journal_title：Alimentary pharmacology & therapeutics

authors： Clooney AG,Bernstein CN,Leslie WD,Vagianos K,Sargent M,Laserna-Mendieta EJ,Claesson MJ,Targownik LE

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Proton pump inhibitors effectively suppress intragastric acid. Nocturnal acid breakthrough occurs on any dosing regimen of oral proton pump inhibitors. Histamine(2)-receptor antagonists (H(2)RA) suppress intragastric acidity independently of meals and help to control nocturnal acid breakthrough. Because prot...

journal_title：Alimentary pharmacology & therapeutics

authors： Tutuian R,Katz PO,Ahmed F,Korn S,Castell DO

更新日期：2002-03-01 00:00:00

abstract：BACKGROUND:Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS-C clinical trials, recommending a composite endpoint incorporating both...

journal_title：Alimentary pharmacology & therapeutics

authors： Chang L,Chey WD,Drossman D,Losch-Beridon T,Wang M,Lichtlen P,Mareya S

更新日期：2016-11-01 00:00:00